


TNG-462

Cat. No.:	HY-156680		
CAS No.:	2760483-96-1		
Molecular Formula:	C ₂₈ H ₃₆ N ₆ O ₂ S		
Molecular Weight:	520.69		
Target:	Histone Methyltransferase		
Pathway:	Epigenetics		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (192.05 mM; Need ultrasonic)					
		Solvent Concentration	Mass	1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM		1.9205 mL	9.6026 mL	19.2053 mL
		5 mM		0.3841 mL	1.9205 mL	3.8411 mL
10 mM			0.1921 mL	0.9603 mL	1.9205 mL	
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (4.80 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (4.80 mM); Clear solution					
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (4.80 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	TNG-462 (Compound 1143) is an orally active PRMT5 inhibitor for investigation of MTAP-deficient and/or MTA-accumulating cancers ^[1] .
IC ₅₀ & Target	PRMT5 ^[1] .

REFERENCES

[1]. Kevin M Cottrell, et al. Piperidin-1-yl-n-pyridine-3-yl-2-oxoacetamide derivatives useful for the treatment of mta-deficient and/or mta-accumulating cancers. Patent WO2022026892A1.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA